4 Healthcare Stock Stories For a Thursday Investment Checkup

Humana Inc. (NYSE:HUM): Closing price $93.19

On Thursday, Humana and Eli Lilly and Co. announced a joint research arrangement that targets improving the health care of their members and patients. Through the partnership, the firms will employ their expertise and resources so as to identify and analyze data and information, centering on improving health care quality and outcomes. The collaboration reflects a shared commitment by both parties to meet the challenges of improving quality of care and reducing treatment costs in the contemporary complex and changing health care environment.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

HUM-20130829

Becton, Dickinson and Co. (NYSE: BDX): Closing price $97.58

Becton, Dickinson’s wholly-owned subsidiary BD Rx Inc. announced Thursday that the FDA has okayed the third drug to be offered in the new BD Simplist line of ready-to-administer prefilled generic injectables. The third BD Simplist product to debut is Ondansetron Injection, USP 4mg/2mL (2mg/mL), which is an injectable antiemetic. Ondansetron Injection, USP which is used to block postoperative nausea and vomiting, is presently on the FDA drug shortage list because of recent demand increases and supply problems experiencd by other manufacturers. Additionally, Ondansetron Injection, USP can be used with initial and repeat courses of emetogenic cancer chemotherapy.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BDX-20130829

St. Jude Medical Inc. (NYSE:STJ): Closing price $50.60

St. Jude on Thursday announced the CE Mark approval of its next-generation EnligHTN Renal Denervation System used for treating patients having drug-resistant, uncontrolled hypertension. The system contains an advanced generator which provides simultaneous ablations via a multi-electrode catheter, reducing total ablation time with the new EnligHTN system by over 80 percent, versus the first generation system, from about 24 minutes to four minutes. The EnligHTN system presented during the 2013 European Society of Cardiology meeting from August 31 to September 3.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

STJ-20130829

Arena Pharmaceuticals Inc. (NASDAQ:ARNA): Closing price $6.35

Arena has said a patient being treated with its experimental lung drug experienced a heart rhythm disorder, raising fears about the drug’s safety. The firm said that its trial investigator thought that the heart rhythm disorder could be possibly related to the treatment. In a Wednesday statement, Arena said that there were no serious adverse events observed in the trial but revised it on Thursday so as to include the transient atrial fibrillation event that occurred in one patient.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ARNA-20130829

Don’t Miss: American Public: Confused as Ever About Obamacare.